|
|
| | Ningetinib Basic information |
| Product Name: | Ningetinib | | Synonyms: | CS-2653;Ningetinib-Tosylate(free base);Ningetinib;Ningetinib(free base);CT053PTSA;1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-;N-(3-fluoro-4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide;Vascular endothelial growth factor receptor,inhibit,c-Met/HGFR,TAM Receptor,Mer,Tyro3,VEGFR,Ningetinib,Axl,Inhibitor | | CAS: | 1394820-69-9 | | MF: | C31H29FN4O5 | | MW: | 556.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1394820-69-9.mol |  |
| | Ningetinib Chemical Properties |
| density | 1.348±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 15 mg/ml; DMF:PBS (pH 7.2) (1:5): 0.16 mg/ml; DMSO: 2 mg/ml | | form | A crystalline solid | | pka | 11.00±0.70(Predicted) |
| | Ningetinib Usage And Synthesis |
| Uses | Ningetinib, is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. |
| | Ningetinib Preparation Products And Raw materials |
|